%0 Journal Article %A Zhi Yu %A Seyedeh M. Zekavat %A Sara Haidermota %A Rachel Bernardo %A Peter Libby %A Hilary Finucane %A Pradeep Natarajan %T Genome-wide pleiotropy analysis of coronary artery disease and pneumonia identifies shared immune pathways %D 2021 %R 10.1101/2021.07.05.21260028 %J medRxiv %P 2021.07.05.21260028 %X Coronary artery disease (CAD) remains the leading cause of death despite scientific advances. Elucidating shared CAD/pneumonia pathways may reveal novel insights regarding CAD pathways. We performed genome-wide pleiotropy analyses of CAD and pneumonia, examined the causal effects of the expression of genes near independently replicated SNPs and interacting genes with CAD and pneumonia, and tested interactions between disruptive coding mutations of each pleiotropic gene and smoking status on CAD and pneumonia risks. Identified pleiotropic SNPs were annotated to ADAMTS7 and IL6R. Increased ADAMTS7 expression across tissues consistently showed decreased risk for CAD and increased risk for pneumonia; increased IL6R expression showed increased risk for CAD and decreased risk for pneumonia. We similarly observed opposing CAD/pneumonia effects for NLRP3. Reduced ADAMTS7 expression conferred a reduced CAD risk without increased pneumonia risk only among never-smokers. Genetic immune-inflammatory axes of CAD linked to respiratory infections implicate ADAMTS7 and IL6R, and related genes.Competing Interest StatementP.L. is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer and Sanofi-Regeneron. P.L. is a member of scientific advisory board for Amgen, Caristo, Cartesian, Corvidia Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec and XBiotech, Inc. P.L.'s laboratory has received research funding in the past 2 years from Novartis. P.L. is on the Board of Directors of XBiotech, and has a financial interest in Xbiotech, a company developing therapeutic human antibodies. P.L.'s interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. P.N. reports investigator-initiated grants from Amgen, Apple, Boston Scientific, and AstraZeneca, personal fees from Apple, Blackstone Life Sciences, Foresite Labs, Genentech, and Novartis, and spousal employment at Vertex, all unrelated to the present work.Funding StatementH.K.F. was funded by NIH grant DP5 OD024582 and by Eric and Wendy Schmidt. P.N. is supported by grants from the National Heart, Lung, and Blood Institute (R01HL142711, R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of the UK Biobank data was approved by the Massachusetts General Hospital Institutional Review Board (protocol 2013P001840) and facilitated through UK Biobank Applications 7089 and 21552. Mass General Brigham Biobank analyses were approved by the Massachusetts General Hospital Institutional Review Board (protocol 2020P000904).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUKB individual-level data are available for request by application (https://www.ukbiobank.ac.uk). Individual-level MGBB data are available from https://personalizedmedicine.partners.org/Biobank/Default.aspx, but restrictions apply to the availability of these data. All the summary-level data used are available for download at the public repositories. %U https://www.medrxiv.org/content/medrxiv/early/2021/07/07/2021.07.05.21260028.full.pdf